• 20/20 Biolabs started contingency planning to stand up Ebola and hantavirus PCR testing in its CAP-accredited CLIA lab if outbreak-driven demand exceeds public health lab capacity.
• Plans include engaging PCR test kit developers globally to line up supply options, aiming to reduce near-term constraints if a rapid scale-up is needed.
• The company is assessing whether PCR equipment used during the COVID-19 pandemic can be repurposed to speed assay validation and potential deployment.
• Management framed the effort as a platform-flexible strategy designed to accelerate validation work if public health agencies, researchers, or partners request surge testing support.
• The initiative does not signal regulatory authorization, clinical availability, or a decision to commercialize Ebola or hantavirus tests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 20/20 Biolabs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605220831PRIMZONEFULLFEED9725116) on May 22, 2026, and is solely responsible for the information contained therein.